This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.

The present invention relates to compositions comprising: a polypeptide having cellulolytic enhancing activity and a liquor. The present invention also relates to methods of using the compositions.

The present invention relates to compositions comprising: a polypeptide having cellulolytic enhancing activity and a liquor. The present invention also relates to methods of using the compositions.

Compounds of the formula I

##STR00001## in which R.sup.1 denotes A, Ar, Cyc, Het, COA or CN, R.sup.2 denotes SO.sub.2A, SOA, SA, SO.sub.2NHA, SO.sub.2NA.sub.2, S(═NH,═O)A, S(═NH).sub.2A, NO.sub.2, Hal, CN, A, Het.sup.1, COOH or COOA, R.sup.3 denotes H or Hal, R.sup.4 denotes H or Hal, n denotes 1, 2 or 3, A denotes unbranched or branched alkyl having 1-6 C-atoms, Cyc denotes cyclic alkyl with 3 to 7 C-atoms, Ar denotes phenyl, Het denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, Het.sup.1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, and Hal denotes F, Cl, Br, or I, are inhibitors of HIF-2α, and can be employed for the treatment of diseases such as cancer.

Compounds of the formula I

##STR00001## in which R.sup.1 denotes A, Ar, Cyc, Het, COA or CN, R.sup.2 denotes SO.sub.2A, SOA, SA, SO.sub.2NHA, SO.sub.2NA.sub.2, S(═NH,═O)A, S(═NH).sub.2A, NO.sub.2, Hal, CN, A, Het.sup.1, COOH or COOA, R.sup.3 denotes H or Hal, R.sup.4 denotes H or Hal, n denotes 1, 2 or 3, A denotes unbranched or branched alkyl having 1-6 C-atoms, Cyc denotes cyclic alkyl with 3 to 7 C-atoms, Ar denotes phenyl, Het denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, Het.sup.1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, and Hal denotes F, Cl, Br, or I, are inhibitors of HIF-2α, and can be employed for the treatment of diseases such as cancer.

Provided are a condensed cyclic compound represented by Formula 1 and an organic light-emitting device including the same:

##STR00001##

wherein, in Formula 1, X.sub.1, A.sub.1, L.sub.11, a11, Ar.sub.11, Ar.sub.12, b11, R.sub.11, R.sub.12, c11, and c12 are the same as defined in the specification.

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases. ##STR00001##

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases. ##STR00001##

The present invention provides novel heterocylic amide compounds having useful antimycobacterial activity. Use of these compounds as pharmaceutical compositions and method of their production are also provided.